Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Less Than Half Of ODAC Members Will Participate In Avastin Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

The "jury" for FDA's June 28-29 hearing on Avastin's breast cancer indication will consist of only six voting participants, five of whom previously called for the claim's withdrawal.
Advertisement

Related Content

Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say
Avastin On Trial: The Jurors (Updated)
Avastin Hearing: Witnesses For The Prosecution And Defense
An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
Genentech's Hopes For Avastin In Breast Cancer May Rest With New ODAC Members
Genentech's Hopes For Avastin In Breast Cancer May Rest With New ODAC Members

Topics

Advertisement
UsernamePublicRestriction

Register

PS072414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel